TLPH News & Events

Cash and investments balance was $21.1M as of March 31. "In early March, we announced the attainment of 50% enrollment in the NEPHRO CRRT study evaluating nafamostat. With continued steady enrollment, we have well exceeded this level, and continue to expect study completion later this year," stated Vince Angotti, CEO. "Our clinical study sites and principal investigators remain focused on enrollment and delivering a high quality study as they are eager for a potential alternative anticoagulant for Continuous Renal Replacement Therapy. The investor and analyst event held in March also highlighted the need for an alternative, given the disadvantages of the currently used products, heparin and citrate. If approved, we continue to believe nafamostat will fill an unmet need in the market as a regional anticoagulant for CRRT".

Talphera files to sell 639,931 shares of common stock for holders

The major averages closed sharply higher after President Donald Trump said the U.S. and Iran have held talks and that he was ceasing plans to attack Iranian power plants and energy infrastructure. Of note, however, AP reported that two Iranian semi-official news agencies close to the paramilitary Revolutionary Guard claim that there have been no such negotiations. Following Trump's comments, oil prices sharply pulled back, while shares of airlines and cruise lines advanced.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Elon Musk plans to start his Terafab project, which will be run by Teslaand SpaceX, in Austin, Texas,U.S. Senators have introduced a bill aiming to ban sports bets on prediction markets,Activist investor Elliot Management has built a stake in Synopsys,Palantir'sMaven AI system will be adopted by the Pentagon as a core military system,Delta Air Linessaid thatat New York's LaGuardia Airport following the collision of an Air Canadaplane into a Port Authority firetruck that resulted in two pilot deaths2. WALL STREET CALLS:MongoDBto Outperform from Neutral at MizuhoRaymond JamesAeroVironmentafter share underperformanceValvolineto Buy at StifelMacquarieXPengwith 2026 volume growth "no guarantee"William Blaira handful of names in infrastructure software, including Backblaze, N-able, GitLaband Dropboxto Underperform3. AROUND THE WEB:Gileadis near a deal to buy Ouro Medicines for up to $2B, FT reportsOpenAI offers buyout firms sweeter deals than Anthropic, Reuters reportsSonyis close to a deal to sell a majority stake in its home entertainment business to Chinese rival TCL Electronicsin a deal that may be valued at about $1B, Bloomberg reportsUnited Airlinesplans to cut additional unprofitable flights over the next two quarters as it braces for sustained high jet fuel prices tied to the Iran war, despite strong travel demand and higher fares, Reuters saysMP MaterialsCEO James Litinsky has repositioned the company as a key U.S. rare earths supplier amid rising geopolitical tensions and Chinese export restrictions, CBS News reports4. MOVERS:Apogee Therapeuticsgained afterfrom Phase A of its Phase 2 APEX trial of zumilokibartTeraWulfadvanced after Areteof the stock with a Buy ratingEstee Lauder (EL) dropped after Puig Brandsconfirmed that it is in discussions regarding a potential business combination with the companyEquinordeclined after230MW Esquina do Vento onshore wind complex from VestasPG&Efell after Jefferiesthe stock to Hold5. EARNINGS/GUIDANCE:Talphera, with EPS higher year-over-yearOndasreportedand provided guidance for FY26 and Q1Solo BrandsprovidedCabaletta Bio, with EPS beating consensusChina Petroleum and Chemicalreported, with EPS and revenue lower year-over-yearINDEXES:The Dow rose 631.00, or 1.38%, to 46,208.47, the Nasdaq gained 299.15, or 1.38%, to 21,946.76, and the S&P 500 advanced 74.52, or 1.15%, to 6,581.00.